Table 1:
Description of participants in 6 prospective cohort studies for meta-analysis of anti-hypertension medications and incident dementia
| Cohort Studies | ||||||
|---|---|---|---|---|---|---|
| Characteristics | AGES-Reykjavik | ARIC | FHS | HAAS | RS | 3C |
| Sample size, No. | 4163 | 5603 | 2379 | 2646 | 7240 | 8236 |
| Women (n,%) | 2467(59.3) | 2762 (49) | 1275(53.6) | 0 | 4166 (57.5) | 5052 (61.3) |
| Race/ethnicity (n,%) | ||||||
| White | 4163 | 5603 | 1961(99.7) | 0 | 7240 (99.7) | NA |
| Black | 0 | 0 | 6(0.3) | 0 | 25 (0.3) | NA |
| Japanese/Asian | 0 | 0 | 0 | 2646 | 0 | NA |
| Education (n,%) | ||||||
| Primary | 866(21.7) | 1283 (23) | 132(5.7) | 1330(50.2) | 849 (11.9) | 2046 (24.8) |
| Secondary | 2005(50.3) | 2437 (44) | 1445(62.6) | 769(29.1) | 3100 (43.3) | 2959 (35.9) |
| College | 649(16.3) | 1460 (26) | 731(31.7) | 278(10.5) | 2047 (28.6) | 1655 (20.1) |
| University | 469(11.8) | 419 (7) | N/A | 269(10.2) | 1165 (16.3) | 1576 (19.1) |
| Age mean (SD),y | 76.2(5.5) | 59.42 (2.90) | 65.8(7.1) | 76.9(4.1) | 68.9 (8.7) | 74.0 (5.4) |
| Age group, y (n,%) | ||||||
| 55–64 | NA | 5531 (99) | 1173(49.3) | NA | 2790 (38.5) | NA |
| 65–74 | 1780(42.8) | 72 (1) | 914(38.4) | 905(34.2) | 2565 (35.4) | 4724 (57.4) |
| 75–84 | 2076(49.9) | NA | 283(11.9) | 1572(59.4) | 1593 (22.0) | 3123 (37.9) |
| ≥85 | 307(7.4) | NA | 9(0.4) | 169(6.4) | 292 (4.0) | 389 (4.7) |
| Depressive symptoms (n,%) | 273(6.9) | 198(8.5) | 231(8.7) | 661(9.5) | 1077 (13.1) | |
| SBP mean (SD), mmHg | 142.2(20.4) | 122.63 (17.68) | 130.2(19.1) | 149.5(22.0) | 145.6 (21.8) | 146.5 (21.7) |
| DBP mean (SD), +C13:I25mmHg | 73.9 (9.6) | 71.49 (10.13) | 73.5(9.9) | 80.6(10.7) | 80.7 (11.1) | 82.3 (11.3) |
| BP group (n,%) | ||||||
| Normal BP | 2026 (48.7) | 4648 (83) | 1686(70.9) | 898 (33.9) | 2870 (39.6) | 3125 (37.9 |
| High BP | 2137 (51.3) | 955 (17) | 693(29.1) | 1748 (66.1) | 4370 (60.4) | 5111 (62.1) |
| Antihypertensive med use (n,%) | 2585(62.2) | 1821 (33) | 958(40.3) | 1092 (41.3) | 3061 (42.3) | 4138 (50.2) |
| ACEI w/wo others | 531 (12.8) | 212 (4) | 388(16.3) | 227 (8.6) | 2638 (20.1) | 1136 (13.8) |
| ARBs w/wo others | 504(14.5) | 0 (0) | 77(3.2) | 0 | NA | 987 (12.0) |
| BBs w/wo others | 1426(34.3) | 774 (14) | 411(17.3) | 306 (11.6) | 1638 (22.6) | 1387 (16.8) |
| CCBs w/wo others | 658(15.8) | 252 (4) | 292(12.3) | 498 (18.8) | 697 (9.6) | 1090 (13.2) |
| Diuretics w/wo others | 1554(37.3) | 1011 (18) | 349(14.7) | 368 (13.9) | 1036 (14.3) | 506 (6.1) |
| Use of ≥2 AHM | 1504(36.1) | 505 (9) | 469(19.7) | 364 (13.8) | 1353 (18.7) | 1502 (18.2) |
| ApoEε4 (n,%) | 1158(27.9) | 1491 (28) | 524(22.5) | 462 (17.6) | 1857 (27.4) | 1577 (19.1) |
| BMI, mean (SD) | 27.1(4.3) | 27.08 (4.65) | 28.2(5.2) | 23.7(3.0) | 27.7 (4.2) | 25.7 (4.0) |
| Diabetes (n,%) | 487(11.7) | 651 (12) | 343(15.4) | 592(22.4) | 874 (12.1) | 638 (7.7) |
| eGFR, mean (SD) | 69.0(16.9) | 94.93 (12.36) | 79.5(15.8) | NA | 78.4 (14.6) | 117.2 (41.3) |
| Smoking (n,%) | ||||||
| Never | 1853(45.3) | 2171 (39) | 807(33.9) | 899(35.2) | 2117 (29.6) | 5070 (61.6) |
| Former | 1782(43.4) | 2158 (39) | 1312(55.2) | 1495(58.5) | 3762 (52.0) | 2721 (33.0) |
| Current | 456(11.2) | 1272 (23) | 260(10.9) | 161(6.3) | 1278 (17.7) | 445 (5.4) |
| Cardiovascular disease (n,%) | 854(20.7) | 428 (8) | 391(16.4) | 454(17.2) | 609 (8.4) | 518 (6.3) |
| Stroke (n,%) | 200(4.8) | NA | 57(2.4) | 84(3.2) | 226 (3.1) | 179 (2.2) |
| Atrial fibrillation (n,%) | 353(8.6) | 22 (0.4) | 114(4.8) | 73(2.8) | 382 (5.7) | 162 (2.0) |
| Year of baseline data collection | 2002–2006 | 1987–1989 | 1998–2001 | 1991–1994 | 2002–2008 | 1999–2001 |
| Year of last dementia follow-up | 2015 | 2013 | 2016 | 1999–2000 | 2015 | 2010 |